Highlights: - Share Purchase Plan receives A$4.4 million of valid applications - Total funds raised of A$12.4 million, in conjunction with recently completed A$8.0 million institutional placement - Proceeds will be used to advance clinical trials for intravenous use of R327, topical applications of R327G, including Phase III clinical activities in Indonesia, and IND-enabling activities - Pro forma cash ...
[ more ]
